Screening of Leukemic Neoantigen Specific T cells with the iQue Screener PLUS
Alison Tarke
Monday, February 26, 2018
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Background
PersImmune Process
Objectives
Proliferation of Donor PBMC and peptides measured after 6 days
Proliferation of MDS patient PBMC with leukemic peptides
Access DRS Devices For Acoustic Sample Management
Better Management of Sample Exposure Preserve Sample Integrity
Objectives
T cell killing assay
Forecyt gating strategy
T cell killing assay
Killing of autologous tumor cells by neoantigen-specific autologous T cells
Objectives
Phenotyping with CD45
Phenotyping with CD45 and additional leukocyte markers
Conclusions
Acknowledgements
No transcript for this webinar
More Information
Contact Intellicyt